What Alzheimer's Does to the Brain

In 1906, a German physician named Alois Alzheimer stood before a room of psychiatrists and described a patient he had followed for years. Her name was Auguste Deter, and she had arrived at his clinic in her early fifties, confused, anxious, and slowly losing her grip on the most ordinary details of her life. When asked to write her name, she trailed off and said, "I have lost myself." After she died, Alzheimer examined her brain under a microscope and saw something strange: dense clumps wedged between the nerve cells and tangled fibers coiled inside them. He had no idea what they were made of. More than a century later, those two features, the plaques and the tangles, remain the defining signatures of the disease that now bears his name.

Today around 55 million people worldwide live with dementia, and Alzheimer's disease is the most common cause, accounting for roughly two-thirds of cases. It is not a normal part of aging, and it is not simply "getting forgetful." It is a physical disease of the brain, with a biology that scientists have spent decades trying to untangle. Here is what we actually know about what Alzheimer's does inside the skull.

The two hallmarks Alzheimer saw

When neuroscientists talk about Alzheimer's, they almost always come back to the same two structures, the very ones Alois Alzheimer glimpsed in 1906.

The plaques: These are sticky deposits that build up in the spaces between neurons. They are made mostly of a protein fragment called beta-amyloid, which is snipped from a larger protein that sits in the membranes of brain cells. In a healthy brain, these fragments are cleared away. In Alzheimer's, they accumulate, clump together, and form hard, insoluble plaques that crowd the tissue.

The tangles: Inside the neurons themselves, a protein called tau normally acts like a railway tie, holding together the internal tracks that carry nutrients and signals along the cell. In Alzheimer's, tau becomes chemically altered, detaches, and twists into tangled threads. The internal transport system collapses, and the cell begins to starve and die.

These two features tend to show up in different places and at different times. Amyloid plaques often appear first and spread widely across the outer layers of the brain. Tau tangles tend to track more closely with where symptoms appear and how severe they become. The relationship between the two is one of the central puzzles of the field.

How the damage spreads

Alzheimer's does not strike the whole brain at once. It moves through it in a fairly predictable pattern, almost like a slow tide.

The damage usually begins deep in the brain, in and around a seahorse-shaped structure called the hippocampus, which is essential for forming new memories. This is why one of the earliest and most recognizable symptoms is difficulty holding on to recent events: a person may repeat the same question, forget a conversation from an hour ago, or misplace things in odd locations, all while clearly remembering a holiday from forty years earlier.

From there, the disease creeps outward into the cerebral cortex, the wrinkled outer layer responsible for language, reasoning, judgment, and recognition. As tau pathology spreads into these regions, the symptoms broaden. Word-finding becomes harder. Familiar tasks like managing money or following a recipe slip out of reach. Spatial awareness falters, so a person may get lost on a once-familiar street. In the later stages, the disease reaches areas controlling movement and basic bodily functions.

A striking feature of this spread is that the misfolded proteins appear to move from cell to cell along connected neural pathways, almost as if the disease follows the brain's own wiring. Some researchers describe the abnormal tau as behaving in a "seeding" fashion, where a small amount can trigger nearby healthy protein to misfold too. This idea is still being studied carefully, but it helps explain the orderly, network-based march of the disease.

The amyloid hypothesis, and its critics

For roughly thirty years, the dominant explanation for Alzheimer's has been the amyloid hypothesis: the idea that the buildup of beta-amyloid is the initial trigger that sets off a cascade, including tau tangles, inflammation, and the death of neurons. The strongest support comes from genetics. The rare, inherited forms of early-onset Alzheimer's are caused by mutations in genes that govern how amyloid is produced, and people with Down syndrome, who carry an extra copy of the relevant chromosome, develop amyloid plaques and Alzheimer's at strikingly high rates.

But the hypothesis has had a rough decade. Many drugs designed to clear amyloid from the brain succeeded in removing the plaques yet failed to meaningfully stop the decline in patients. This led to a long, sometimes heated debate. Critics argued that amyloid might be more of a bystander or a late-stage marker than the true driver, and that the field had become too narrowly focused on a single protein. Others countered that the drugs were simply given too late, after too much damage was already done, and that the right move was to treat people earlier, before symptoms appear.

The honest summary is that scientists still debate exactly how central amyloid is. What is clear is that the disease is more complicated than any single protein. Inflammation, the brain's immune cells, blood vessel health, and tau all play important roles, and the interplay between them is an active frontier of research.

The risk factors you can and cannot change

Alzheimer's is not caused by one thing. It emerges from a mix of factors, some fixed and some that appear to be at least partly within our influence.

Age is by far the biggest risk factor. The disease is uncommon before 65, and the likelihood roughly increases with each additional decade of life. This is why an aging global population means rising numbers of cases.

Genetics matter too. Beyond the rare inherited early-onset forms, the most well-established genetic influence on common late-onset Alzheimer's is a gene variant called APOE4. Carrying one or two copies raises risk, though it is important to stress that having APOE4 does not guarantee the disease, and many people who develop Alzheimer's do not carry it at all.

Lifestyle and vascular health appear to play a meaningful role. Large reviews have identified factors that are linked to dementia risk and are potentially modifiable, including high blood pressure, diabetes, smoking, hearing loss, physical inactivity, social isolation, depression, and limited education earlier in life. These are associations rather than proof of direct cause, and no single habit is a guarantee in either direction. Still, the broad message from researchers is encouraging: what is good for the heart and blood vessels tends to be good for the brain, and staying physically, socially, and mentally active is sensible.

What we can and cannot do about it

For most of the disease's history, treatments could only soften symptoms. A handful of older medications can modestly help with memory and thinking for a time by adjusting brain chemistry, but they do not slow the underlying biology.

The newer chapter involves the antibody drugs that target amyloid directly. In recent years, a small number of these treatments have been authorized in some countries after trials showed they could slow the rate of cognitive decline in people in the early stages of the disease. This was hailed by many as a genuine milestone, the first therapies to touch the disease process itself rather than just the symptoms. But the benefits so far are modest, the drugs require regular infusions and careful monitoring, and they carry a risk of brain swelling and small bleeds that shows up on scans. Their real-world value is still being weighed by doctors and health systems.

Equally important has been progress in diagnosis. Researchers have developed brain scans and spinal fluid tests that can detect amyloid and tau years before severe symptoms appear, and blood tests aimed at flagging the disease earlier and more cheaply are advancing quickly. Detecting the disease early matters more now than ever, because any treatment that targets the biology is likely to work best before too many neurons are lost.

Living with a changing brain

It is worth stepping back from the molecules to remember what this disease actually means for the people who have it. Alzheimer's unfolds over years, often a decade or more, and it does not erase a person all at once. Long-term memories, emotional connection, and the capacity for joy can persist well into the illness even as recent memory fades. Music, familiar faces, and old routines often reach people when words no longer do.

This matters because the most powerful interventions today are not only pharmaceutical. Supportive environments, clear routines, and patient caregiving genuinely improve quality of life. Caregivers, who are most often family members, carry an enormous and frequently invisible burden, and the social cost of the disease is measured not only in medical bills but in the years of devotion it demands. As the science slowly advances, that human dimension remains central.

Key Takeaways

Alzheimer's disease is a physical illness of the brain defined by two abnormal protein features that Alois Alzheimer first saw in 1906: amyloid plaques that build up between neurons and tau tangles that form inside them. The damage typically begins in the memory-forming hippocampus and spreads outward through the brain's networks in a slow, fairly predictable pattern, which is why fading recent memory is usually the first sign and why language, judgment, and orientation erode as it progresses. For decades the amyloid hypothesis has framed the field, but repeated drug failures have kept scientists debating exactly how central amyloid really is, and most now see the disease as a tangle of amyloid, tau, inflammation, and vascular factors working together. Age and genetics like the APOE4 variant raise the risk, while heart-healthy habits appear to lower it, even if no single choice is a guarantee. The first treatments that slow the underlying biology have recently arrived, but their benefits are modest, so the brightest near-term hope lies in detecting the disease earlier and in treating the whole person, not just the plaques.